Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and
induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly …

BACKGROUND The pegylated form of interferon‐α‐2a (PegIFNa2a) in combination with
imatinib has demonstrated a molecular improvement in patients with chronic‐phase chronic …

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age
56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an …

Since interferon-α and imatinib (IM; STI571, Glivec, Gleevec) are effective for the treatment of
chronic myeloid leukemia (CML), and their mechanisms of action are different, we designed …

Tyrosine kinase inhibitor therapy with imatinib (IM), dasatinib (DAS), or nilotinib is very
effective in chronic-phase chronic myeloid leukemia. Two hundred fifty-three patients with …

In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors
(TKIs) aim to improve the achievement of deep molecular remission that would allow therapy …

Background The multikinase inhibitor dasatinib exerts growth‐inhibitory effects in patients
with imatinib‐resistant chronic myeloid leukaemia (CML). In first clinical trials, side effects of …

BACKGROUND: In a phase 3 study, the authors assessed the effects of dasatinib at doses of
140 mg once daily and 70 mg twice daily in patients who had either chronic myeloid …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …

In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400
mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia …